Tags

Type your tag names separated by a space and hit enter

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.
J Am Soc Nephrol. 1995 Jul; 6(1):110-20.JA

Abstract

Numerous studies have investigated lipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical pitfalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 +/- 25.0 mg/dL (P < 0.005; HD) and 34.6 +/- 38.4 mg/dL (P < 0.0001; CAPD) versus 18.4 +/- 22.8 mg/dL (controls). CAPD patients showed significantly higher Lp(a) values than did patients treated by HD (P < 0.001). The difference between the two treatment groups possibly reflects an overproduction of Lp(a) to compensate for protein losses in CAPD patients. Both treatment groups included significantly more patients with Lp(a) values greater than the 75th percentile (25.6 mg/dL) of the control group (33.9 and 41.7% for HD and CAPD, respectively; P < 0.005). The higher Lp(a) values in patients were not explained by differences in isoform frequencies and the increase in Lp(a) was apolipoprotein(a) type specific: only patients with high-molecular-weight apolipoprotein(a) isoforms showed a significant elevation in Lp(a) levels. The increased plasma concentrations of Lp(a) may contribute to the high risk for atherosclerosis in ESRD, especially in patients treated by CAPD. Finally, it is believed that small sample sizes are responsible for the diverging results in Lp(a) literature.

Authors+Show Affiliations

Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7579063

Citation

Kronenberg, F, et al. "Multicenter Study of Lipoprotein(a) and Apolipoprotein(a) Phenotypes in Patients With End-stage Renal Disease Treated By Hemodialysis or Continuous Ambulatory Peritoneal Dialysis." Journal of the American Society of Nephrology : JASN, vol. 6, no. 1, 1995, pp. 110-20.
Kronenberg F, König P, Neyer U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6(1):110-20.
Kronenberg, F., König, P., Neyer, U., Auinger, M., Pribasnig, A., Lang, U., Reitinger, J., Pinter, G., Utermann, G., & Dieplinger, H. (1995). Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. Journal of the American Society of Nephrology : JASN, 6(1), 110-20.
Kronenberg F, et al. Multicenter Study of Lipoprotein(a) and Apolipoprotein(a) Phenotypes in Patients With End-stage Renal Disease Treated By Hemodialysis or Continuous Ambulatory Peritoneal Dialysis. J Am Soc Nephrol. 1995;6(1):110-20. PubMed PMID: 7579063.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. AU - Kronenberg,F, AU - König,P, AU - Neyer,U, AU - Auinger,M, AU - Pribasnig,A, AU - Lang,U, AU - Reitinger,J, AU - Pinter,G, AU - Utermann,G, AU - Dieplinger,H, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 110 EP - 20 JF - Journal of the American Society of Nephrology : JASN JO - J. Am. Soc. Nephrol. VL - 6 IS - 1 N2 - Numerous studies have investigated lipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical pitfalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 +/- 25.0 mg/dL (P < 0.005; HD) and 34.6 +/- 38.4 mg/dL (P < 0.0001; CAPD) versus 18.4 +/- 22.8 mg/dL (controls). CAPD patients showed significantly higher Lp(a) values than did patients treated by HD (P < 0.001). The difference between the two treatment groups possibly reflects an overproduction of Lp(a) to compensate for protein losses in CAPD patients. Both treatment groups included significantly more patients with Lp(a) values greater than the 75th percentile (25.6 mg/dL) of the control group (33.9 and 41.7% for HD and CAPD, respectively; P < 0.005). The higher Lp(a) values in patients were not explained by differences in isoform frequencies and the increase in Lp(a) was apolipoprotein(a) type specific: only patients with high-molecular-weight apolipoprotein(a) isoforms showed a significant elevation in Lp(a) levels. The increased plasma concentrations of Lp(a) may contribute to the high risk for atherosclerosis in ESRD, especially in patients treated by CAPD. Finally, it is believed that small sample sizes are responsible for the diverging results in Lp(a) literature. SN - 1046-6673 UR - https://www.unboundmedicine.com/medline/citation/7579063/Multicenter_study_of_lipoprotein_a__and_apolipoprotein_a__phenotypes_in_patients_with_end_stage_renal_disease_treated_by_hemodialysis_or_continuous_ambulatory_peritoneal_dialysis_ L2 - http://jasn.asnjournals.org/cgi/pmidlookup?view=long&amp;pmid=7579063 DB - PRIME DP - Unbound Medicine ER -